Infectious complications in SLE after immunosuppressive therapies

Current Opinion in Rheumatology

Volumn 15, Issue 5, 2003, Pages 528-534

  Kang, Insoo ^a   Park, Sung Hwan ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The Catholic University of Korea   (South Korea)

Author keywords

Cyclophosphamide; Glucocorticoids; Infection; MMF; SLE

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

BACTERIAL INFECTION; CANDIDIASIS; COMPLEMENT ACTIVATION; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG SAFETY; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; MYCOBACTERIOSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTOZOAL INFECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OPPORTUNISTIC INFECTIONS;

EID: 0042329644     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200309000-00002     Document Type: Review

References (87)

1. Gescuk BD, Davis JC Jr: Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 2002, 4:515-521. This review article summarized newly developed immunosuppressive therapies for SLE, including mycophenolate mofetil and immunoablation followed by stem cell transplantation.
2. Ishikawa O, Abe M, Miyachi Y: Herpes zoster in Japanese patients with systemic lupus erythematosus. Clin Exp Dermatol 1999, 24:327-328.
3. Kahl LE: Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol 1994, 21:84-86.
4. Klemperer P, Pollack AD, Baehr G: Pathology of disseminated lupus erythematosus. Arch Pathol 1941, 32:569.
5. Dillon AM, Stein HB, Kassen BO, et al.: Hyposplenia in a patient with systemic lupus erythematosus. J Rheumatol 1980, 7:196-198.
6. Neilan BA, Berney SN: Hyposplenism in systemic lupus erythematosus. J Rheumatol 1983, 10:332-334.
7. Piliero P, Furie R: Functional asplenia in systemic lupus erythematosus. Semin Arthritis Rheum 1990, 20:185-189.
8. Walport MJ: The Roche Rheumatology Prize Lecture. Complement deficiency and disease. Br J Rheumatol 1993, 32:269-273.
9. Vratsanos G, Kang I, Craft J: Systemic lupus erythematosus. In Samter's Immunologic Diseases, edn 6, vol 2. Edited by Austen KF, Frank MM, Atkinson JP, et al. Philadelphia: Lippincott Williams & Wilkins; 2001:475-495.
10. Petri M: Infection in systemic lupus erythematosus. Rheum Dis Clin North Am 1998, 24:423-456.
11. Juarez M, Misischia R, Alarcon GS: Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am 2003, 29:163-184. This paper reviewed the role of infections in systemic erythematosus, scleroderma, and inflammatory myopathies. This paper focused particularly on the predisposing factors for infections, mortality from infections, and microorganisms responsible for infections.
12. Kim WU, Min JK, Lee SH, et al.: Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 1999, 17:539-545.
13. Petri M, Genovese M: Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. J Rheumatol 1992, 19:1559-1565.
14. Garred P, Madsen HO, Halberg P, et al.: Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 1999, 42:2145-2152.
15. Garred P, Voss A, Madsen HO, et al.: Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2001, 2:442-450.
16. de la Fuente H, Richaud-Patin Y, Jakez-Ocampo J, et al.: Innate immune mechanisms in the pathogenesis of systemic lupus erythematosus (SLE). Immunol Lett 2001, 77:175-180.
17. Passero FC, Myers AR: Decreased numbers of monocytes in inflammatory exudates in systemic lupus erythematosus. J Rheumatol 1981, 8:62-68.
18. Landry M: Phagocyte function and cell-mediated immunity in systemic lupus erythematosus. Arch Dermatol 1977, 113:147-154.
19. Iliopoulos AG, Tsokos GC: Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996, 25:318-336
20. Hsieh SC, Tsai CY, Sun KH, et al.: Decreased spontaneous and lipopolysaccharide stimulated production of interleukin 8 by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Clin Exp Rheumatol 1994, 12:627-633.
21. Boros P, Muryoi T, Spiera H, et al.: Autoantibodies directed against different classes of Fc gamma R are found in sera of autoimmune patients. J Immunol 1993, 150:2018-2024.
22. Yu CL, Chang KL, Chiu CC, et al.: Defective phagocytosis, decreased tumour necrosis factor-alpha production, and lymphocyte hyporesponsiveness predispose patients with systemic lupus erythematosus to infections. Scand J Rheumatol 1989, 18:97-105.
23. Gyimesi E, Kavai M, Kiss E, et al.: Triggering of respiratory burst by phagocytosis in monocytes of patients with systemic lupus erythematosus. Clin Exp Immunol 1993, 94:140-144.
24. Yee AM, Ng SC, Sobel RE, et al.: Fc gammaRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. Arthritis Rheum 1997, 40:1180-1182.
25. Stohl W, Elliott JE, Li L, et al.: Impaired nonrestricted cytolytic activity in systemic lupus erythematosus: involvement of a pathway independent of Fas, tumor necrosis factor, and extracellular ATP that is associated with little detectable perforin. Arthritis Rheum 1997, 40:1130-1137.
26. Stohl W, Hamilton AS, Deapen DM, et al.: Impaired cytotoxic T lymphocyte activity in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: a contributory role for non-T cells. Lupus 1999, 8:293-299.
27. Tsokos GC, Smith PL, Christian CB, et al.: Interleukin-2 restores the depressed allogeneic cell-mediated lympholysis and natural killer cell activity in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1985, 34:379-386.
28. de Luis A, Pigrau C, Pahissa A, et al.: [Infections in 96 cases of systemic lupus erythematosus.] Med Clin (Barc) 1990, 94:607-610.
29. Shyam C, Malaviya AN: Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India. Rheumatol Int 1996, 16:1-3.
30. Paton NI, Cheong IK, Kong NC, et al.: Risk factors for infection in Malaysian patients with systemic lupus erythematosus. Q J Med 1996, 89:531-538.
31. Gladman DD, Hussain F, Ibanez D, et al.: The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002, 11:234-239. These authors performed a nested case-control study at the University of Toronto Lupus Clinic, with prospective follow-up according to a standard protocol since 1970. Using multivariate analysis, one factor remained statistically significant: use of steroids (P = 0.029).
32. Noel V, Lortholary O, Casassus P, et al.: Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 2001, 60:1141-1144.
33. Zonana-Nacach A, Camargo-Coronel A, Yanez P, et al.: Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus 2001, 10:505-510.
34. Cervera R, Khamashta MA, Font J, et al.: Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999, 78:167-175.
35. Nived O, Sturfelt G, Wollheim F: Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med 1985, 55:271-287.
36. Petros D, West S: Overwhelming pneumococcal bacteraemia in systemic lupus erythematosus. Ann Rheum Dis 1989, 48:333-335.
37. Van der Straeten C, Wei N, Rothschild J, et al.: Rapidly fatal pneumococcal septicemia in systemic lupus erythematosus. J Rheumatol 1987, 14:1177-1180.
38. DiNubile MJ, Albornoz MA, Stumacher RJ, et al.: Pneumococcal soft-tissue infections: possible association with connective tissue diseases. J Infect Dis 1991, 163:897-900.
39. Parada JP, Maslow JN: Clinical syndromes associated with adult pneumococcal cellulitis. Scand J Infect Dis 2000, 32:133-136.
40. Ward MM, Pyun E, Studenski S: Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 1995, 38:1492-1499.
41. Hellmann DB, Petri M, Whiting-O'Keefe Q: Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 1987, 66:341-348.
42. Pryor BD, Bologna SG, Kahl LE: Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996, 39:1475-1482.
43. Abramson S, Kramer SB, Radin A, et al.: Salmonella bacteremia in systemic lupus erythematosus. Eight-year experience at a municipal hospital. Arthritis Rheum 1985, 28:75-79.
44. Lim E, Koh WH, Loh SF, et al.: Non-typhoidal salmonellosis in patients with systemic lupus erythematosus. A study of fifty patients and a review of the literature. Lupus 2001, 10:87-92.
45. Edelen JS, Lockshin MD, LeRoy EC: Gonococcal arthritis in two patients with active lupus erythematosus. A diagnostic problem. Arthritis Rheum 1971, 14:557-559.
46. Quismorio FP, Dubois EL: Septic arthritis in systemic lupus erythematosus. J Rheumatol 1975, 2:73-82.
47. Schenfeld L, Gray RG, Poppo MJ, et al.: Bacterial monarthritis due to Neisseria meningitidis in systemic lupus erythematosus. J Rheumatol 1981, 8:145-148.
48. Mitchell SR, Nguyen PQ, Katz P: Increased risk of neisserial infections in systemic lupus erythematosus. Semin Arthritis Rheum 1990, 20:174-184.
49. Feng PH, Tan TH: Tuberculosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1982, 41:11-14.
50. Yun JE, Lee SW, Kim TH, et al.: The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 2002, 20:127-132.
51. Victorio-Navarra ST, Dy EE, Arroyo CG, et al.: Tuberculosis among Filipino patients with systemic lupus erythematosus. Semin Arthritis Rheum 1996, 26:628-634.
52. Hsu PY, Yang YH, Hsiao CH, et al.: Mycobacterium kansasii infection presenting as cellulitis in a patient with systemic lupus erythematosus. J Formos Med Assoc 2002, 101:581-584.
53. Gaitonde S, Pathan E, Sule A, et al.: Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002, 61:251-253. This study evaluated the efficacy of isoniazid prophylaxis in preventing tuberculosis in patients with SLE who lived in tuberculosis endemic areas. Patients treated with isoniazid for a year had a lower frequency of tuberculosis compared with a historical cohort from the same region.
54. Gilliland WR, Tsokos GC: Prophylactic use of antibiotics and immunisations in patients with SLE. Ann Rheum Dis 2002, 61:191-192.
55. Nagasawa K, Yamauchi Y, Tada Y, et al.: High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 1990, 49:630-633.
56. Genovese MC, Uhrin Z, Bloch DA, et al.: Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. Arthritis Rheum 2002, 46:1014-1018.
57. Tokunaga Y, Takenaka K, Asayama R, et al.: Cytomegalovirus-induced interstitial pneumonitis in a patient with systemic lupus erythematosus. Intern Med 1996, 35:517-520.
58. Ikura Y, Matsuo T, Ogami M, et al.: Cytomegalovirus associated pancreatitis in a patient with systemic lupus erythematosus. J Rheumatol 2000, 27:2715-2717.
59. Sakamoto O, Ando M, Yoshimatsu S, et al.: Systemic lupus erythematosus complicated by cytomegalovirus-induced hemophagocytic syndrome and colitis. Intern Med 2002, 41:151-155.
60. Harisdangkul V, Nilganuwonge S, Rockhold L: Cause of death in systemic lupus erythematosus: a pattern based on age at onset. South Med J 1987, 80:1249-1253.
61. Massardo L, Martinez ME, Baro M, et al.: [Infections in systemic lupus erythematosus.] Rev Med Chil 1991, 119:1115-1122.
62. Ramos L, Lopez C, Gomez C, et al.: Case report. Cutaneous cryptococcosis in a patient with systemic erythematous lupus. Mycoses 2001, 44:419-421.
63. Wong KL: Pattern of SLE in Hong Kong Chinese: a cohort study. Scand J Rheumatol 1992, 21:289-296.
64. Liam CK, Wang F: Pneumocystis carinii pneumonia in patients with systemic lupus erythematosus. Lupus 1992, 1:379-385.
65. Sharma CP, Chaudhary D, Behera D: Pneumocystis carinii pneumonia in a patient with active untreated systemic lupus erythematosus. Indian J Chest Dis Allied Sci 2001, 43:169-171.
66. Duffy KN, Duffy CM, Gladman DD: Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 1991, 18:1180-1184.
67. Lee P, Urowitz MB, Bookman AA, et al.: Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977, 46:1-32.
68. Ginzler E, Diamond H, Kaplan D, et al.: Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978, 21:37-44.
69. Austin HA III, Klippel JH, Balow JE, et al.: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986, 314:614-619.
70. Mok CC, Ho CT, Siu YP, et al.: Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001, 38:256-264.
71. Fauci AS, Dale DC, Balow JE: Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976, 84:304-315.
72. Riccardi C, Bruscoli S, Migliorati G: Molecular mechanisms of immunomodulatory activity of glucocorticoids. Pharmacol Res 2002, 45:361-368.
73. Boumpas DT, Chrousos GP, Wilder RL, et al.: Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993, 119:1198-1208.
74. Staples PJ, Gerding DN, Decker JL, et al.: Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 1974, 17:1-10.
75. Suh CH, Jeong YS, Park HC, et al.: Risk factors for infection and role of C. reactive protein in Korean patients with systemic lupus erythematosus. Clin Exp Rheumatol 2001, 19:191-194.
76. Badsha H, Kong KO, Lian TY, et al.: Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus 2002, 11:508-513. This study evaluated retrospectively the effect of low- (1 to 1.5 g) and high- (3 to 5 g) dose methylprednisolone in patients with SLE. Despite high- and low-dose methylprednisolone being efficacious in controlling disease activity (lowering of SLE disease activity index (SLEDAI) scores and subsequent prednisolone dose) there were only nine episodes of serious infection in seven patients of the low-dose group compared with 20 episodes in 17 patients from the high-dose group (P = 0.04).
77. Houssiau FA, Vasconcelos C, D'Cruz D, et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121-2131. This study evaluated 90 SLE patients with proliferative glomerulonephritis who were assigned to a high-dose IV cyclophosphamide (CYC) regimen (six monthly pulses and two quarterly pulses; doses increased according to the white blood cell count nadir) or a low-dose IV CYC regimen (six fortnightly pulses at a fixed dose of 500 mg), each of which was followed by azathioprine (AZA). The frequency of herpes zoster was twofold higher in patients treated with high-dose cyclophosphamide than in patients treated with low-dose cyclophosphamide.
78. Illei GG, Austin HA, Crane M, et al.: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001, 135:248-257.
79. Gladstone DE, Prestrud AA, Pradhan A, et al.: High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus 2002, 11:405-410.
80. Petri M, Jones RJ, Brodsky RA: High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003, 48:166-173. This study investigated the safety and efficacy of high-dose cyclophosphamide (200 mg/kg) without stem cell transplantation in 14 patients with refractory SLE. All patients received prophylaxis with dapsone, norfloxacin, fluconazole, and valacyclovir. No mortality or fungal infection was noticed.
81. Gourley MF, Austin HA III, Scott D, et al.: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996, 125:549-557.
82. Chan AY, Hooi LS: Outcome of 85 lupus nephritis patients treated with intravenous cyclophosphamide: a single centre 10 year experience. Med J Malaysia 2000, 55:14-20.
83. Hu W, Liu Z, Chen H, et al.: Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002, 115:705-709. This study was an open-label prospective trial for comparing the therapeutic effects of MMF versus cyclophosphamide pulse therapy in patients with diffuse proliferative lupus nephritis. The frequency of infection was 17.4% in the MMF group and 30.4% in the cyclophosphamide group.
84. Karim MY, Alba P, Cuadrado MJ, et al.: Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002, 41:876-882.
85. Musso M, Porretto F, Crescimanno A, et al.: Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Lupus 1998, 7:492-494.
86. Traynor AE, Barr WG, Rosa RM, et al.: Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002, 46:2917-2923. This study determined the safety and long-term efficacy of immune ablation and autologous hematopoietic stem cell transplantation in severe SLE. In this trial, seven cases of infectious complications were noticed, and none of the patients died of infection.
87. Traynor AE, Schroeder J, Rosa RM, et al.: Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 2000, 356:701-707.